晚期肝细胞癌与MET放大含有良好的反应crizotinib:一个病例报告
Yangjun Gu1, Min Xiao1, Zhitao Chen1
1Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
Frontiers in oncology
|September 1, 2023
概括
下一代测序 (NGS) 在肝细胞癌 (HCC) 患者中确定了MET放大. 用MET抑制剂向治疗导致瘤缩和持续缓解,突出显示NGS.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝细胞癌 (HCC) 是全球癌症相关死亡的主要原因.
- 晚期HCC的治疗策略受到瘤异质性的限制.
- 生物标志物对于指导HCC治疗决策至关重要.
研究的目的:
- 调查下一代测序 (NGS) 在识别高级HCC可操作突变方面的实用性.
- 在HCC患者的NGS发现基础上评估向治疗的疗效.
主要方法:
- 一名56岁的男性有B型肝炎和HCC病史,瘤复发.
- 进行下一代测序 (NGS) 来分析瘤遗传变化.
- 根据NGS结果,开始使用MET抑制剂crizotinib治疗.
主要成果:
- 在重复的HCC中,NGS揭示了MET放大.
- 在接受了crizotinib治疗后,患者经历了瘤标志物减少和瘤缩.
- 患者在不确定的时间内实现了持续缓解.
结论:
- NGS可以识别可向的基因变异,如HCC中MET放大.
- MET抑制剂在MET放大HCC患者中显示出显著的疗效.
- 作为个性化HCC治疗的临床决策支持工具,NGS具有潜力.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


